Clinuvel Pharmaceuticals Ltd (CLVLF) company profile

CLINUVEL PHARMACEUTICALS LIMITED is a biopharmaceutical company focused on the development and commercialization of treatments for severe genetic, skin, and metabolic disorders. The company's primary commercial product is SCENESSE, a systemic photoprotective drug designed for the prevention of phototoxicity in adult patients suffering from erythropoietic protoporphyria. In addition to commercializing SCENESSE, the company undertakes clinical development programs, including evaluations of therapeutic candidates for conditions such as vitiligo. Its customer base includes accredited medical centers and hospitals that administer specialized treatments, along with patients receiving therapies through commercial sales and special access reimbursement programs.

The company operates internationally, commercializing its therapies across regions including the United States, Europe, Canada, Israel, and Australia, while conducting clinical trials globally. Contract manufacturing operations for its active pharmaceutical ingredient take place in China. CLINUVEL maintains its principal executive offices and headquarters in Melbourne, Australia.

Summary of the business section of Clinuvel Pharmaceuticals's latest annual report, written by StockData.